You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

 

Online download statistics by month:

Online download statistics by month: July 2021 to July 2025

AbstractFullPdf
Jul 202118218227
Aug 2021598598106
Sep 202114114163
Oct 202113113122
Nov 2021979630
Dec 2021939432
Jan 2022464725
Feb 2022464816
Mar 2022666727
Apr 2022434330
May 2022505121
Jun 2022454721
Jul 2022515826
Aug 2022666615
Sep 2022595923
Oct 2022596225
Nov 2022282818
Dec 2022333311
Jan 2023202010
Feb 2023808117
Mar 2023373734
Apr 2023313224
May 2023373722
Jun 2023434310
Jul 2023171710
Aug 202329299
Sep 2023343416
Oct 2023272714
Nov 2023262616
Dec 2023323315
Jan 2024383915
Feb 2024373725
Mar 2024303037
Apr 2024303023
May 2024343425
Jun 2024403917
Jul 2024404123
Aug 2024323122
Sep 2024282811
Oct 2024545429
Nov 2024394019
Dec 2024404221
Jan 2025454720
Feb 2025313116
Mar 2025353519
Apr 2025585832
May 2025444425
Jun 2025393922
Jul 2025110
Total294229671136